Cellectar Biosciences, Inc. to Post FY2026 Earnings of $0.96 Per Share, Roth Capital Forecasts (NASDAQ:CLRB)

Cellectar Biosciences, Inc. (NASDAQ:CLRB) – Research analysts at Roth Capital decreased their FY2026 EPS estimates for Cellectar Biosciences in a research report issued on Wednesday, July 24th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn $0.96 per share for the year, down from their previous estimate of $0.97. The consensus estimate for Cellectar Biosciences’ current full-year earnings is ($1.43) per share. Roth Capital also issued estimates for Cellectar Biosciences’ FY2027 earnings at $1.99 EPS.

Cellectar Biosciences (NASDAQ:CLRB) last released its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($0.40) EPS for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.10.

Cellectar Biosciences Stock Performance

Cellectar Biosciences stock opened at $2.15 on Monday. The business’s fifty day moving average is $2.76 and its two-hundred day moving average is $3.27. The firm has a market cap of $77.08 million, a P/E ratio of -0.70 and a beta of 0.99. Cellectar Biosciences has a 52 week low of $1.56 and a 52 week high of $4.45.

Institutional Investors Weigh In On Cellectar Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Rosalind Advisors Inc. lifted its position in shares of Cellectar Biosciences by 335.4% during the second quarter. Rosalind Advisors Inc. now owns 2,705,616 shares of the biopharmaceutical company’s stock worth $6,764,000 after purchasing an additional 2,084,138 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Cellectar Biosciences in the 4th quarter valued at $3,817,000. AIGH Capital Management LLC boosted its position in Cellectar Biosciences by 182.7% in the 4th quarter. AIGH Capital Management LLC now owns 1,915,220 shares of the biopharmaceutical company’s stock valued at $5,305,000 after buying an additional 1,237,709 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Cellectar Biosciences by 146.7% in the 1st quarter. Vanguard Group Inc. now owns 1,191,081 shares of the biopharmaceutical company’s stock valued at $4,741,000 after buying an additional 708,191 shares during the period. Finally, Worth Venture Partners LLC raised its position in shares of Cellectar Biosciences by 148.6% during the fourth quarter. Worth Venture Partners LLC now owns 693,909 shares of the biopharmaceutical company’s stock worth $1,922,000 after acquiring an additional 414,786 shares during the last quarter. Institutional investors and hedge funds own 16.41% of the company’s stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer.